Annual Report 2019 and Decision Documents for the Annual General Meeting 5 May 2020

Invent Medic Sweden AB today presents the Annual Report for 2019 and the Proposal for Decision for the upcoming Annual General Meeting on May 5, 2020 in Lund.

CEO Karin Bryder summarises the year
2019 was characterised by a commercial breakthrough for Invent Medic’s first product Efemia bladder support. During
the year, we were able to successfully establish the product and present upcoming launches in six European countries,
including the UK and Germany, and the sales numbers for Efemia began to gain momentum in Q4. Additionally, the
first Efemia order was received from a Swedish healthcare region. After the end of the year, a fully subscribed share
issue of 29.8 MSEK (before issuing costs) was conducted. This will allow us to continue our expansion and offer Efemia
in additional European markets and the United States within three years. We have been affected by the Covid-19
pandemic, with marketing activities being postponed or cancelled, but our sales in Q1 2020 remained stable and we
expect the total sales figure to be in line with Q4 2019. Additionally, we do not expect our ongoing preparations for the
launch in the United States to be affected by this situation.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com 

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.